NICE has issued final guidance not recommending Celgene's multiple myeloma treatment Imnovid (pomalidomide). Imnovid was approved in August 2013 for treating patients with multiple myeloma in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Patients with multiple myeloma will not get routine access to Celgene’s Imnovid (pomalidomide) on the National Health Service, cost regulators have now confirmed. Patients with multiple myeloma will ...
The National Institute for Health and Care Excellence has published draft guidelines recommending 'routine' use of Celgene's Imnovid on the NHS in England and Wales to treat some patients with ...
(RTTNews) - Celgene Corp. (CELG) said Friday that the European Medicines Agency or EMA's Committee for Medicinal Products for Human Use or CHMP has adopted positive opinions for two triplet regimens ...
JERUSALEM (Reuters) - Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, ...
England's cost-effectiveness gatekeeper is singing an increasingly harsh tune when it comes to greenlighting cancer drugs, and Celgene's ($CELG) Imnovid is the latest ...
IMNOVID 4 mg/d on days 1-14 (PVd arm only); bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 of cycles 1-8 and on days 1 and 8 of cycles 9 and beyond; and dexamethasone 20 mg/d (10 mg if aged > 75 years) ...
NICE has issued preliminary draft guidance not recommending Celgene's multiple myeloma treatment Imnovid (pomalidomide). Imnovid was approved in August 2013 for treating multiple myeloma after two ...
The U.K.'s cost-effectiveness watchdog has recently sounded a bit like a broken record when it comes to its cancer drug rejections. The latest to get a "no-go" from ...
Celgene Corporation CELG announced that the European Commission (EC) has approved the label expansion of IMiD medications: leading oncology drug Revlimid (lenalidomide) and Imnovid. The EC approved ...
Jerusalem: Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results